Abstract
Percutaneous ventricular assist device (pVAD) support in cardiogenic shock (CS) patients has been associated with lower costs, shorter lengths of stay (LOS) and reduced readmissions when compared to extracorporeal membrane oxygenation (ECMO) support. The hospital cost and utilization profile of an
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.